News

C&EN6d
(E)-Propyl α-Cyano-4-Hydroxyl Cinnamylate: A High Sensitive and Salt Tolerant Matrix for Intact Protein Profiling by MALDI Mass Spectrometry
Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...
Consumer Reports10d
How to Get PFAS Out of Your Drinking Water
Until federal regulations are resolved, consumers will need to rely on individual state action and their own awareness of PFAS levels in their water. Currently, 11 states (Maine, Massachusetts ...
C&EN16d
Liquid Water: Ubiquitous Contributor to Aerosol Mass
Aerosol liquid water (ALW) is a ubiquitous component of atmospheric aerosol and influences particle chemistry, visibility, human health, and regional climate. The global abundance and spatial patterns ...
Seeking Alpha16d
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
Now that the FDA's grace period has ended, any entity that mass produces or sells knockoff "semaglutide" is breaking the law and putting patient safety at risk. Attempts by compounders to evade ...
WHNT16d
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...
WBOY16d
New Novo Nordisk initiatives support patient access to authentic, FDA-approved Wegovy® as federal ban on mass compounding of "semaglutide" takes effect
PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...
Seeking Alpha16d
Viking Therapeutics: Weight-Loss Story Remains Intact
The weight-loss drug sector has lost a lot of momentum in 2025. The leading drug stocks have slipped since a peak in 2024, pulling down the small biotechs trying to produce competing drugs. As ...